Literature DB >> 12379580

Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes: implications for ischemic sodium loading.

Caroline Pinet1, Bruno Le Grand, Gareth W John, Alain Coulombe.   

Abstract

BACKGROUND: Thrombin plays a role in mediating ischemic injury and cardiac arrhythmias, but the mechanisms involved are poorly understood. Because voltage-gated sodium channels (VGSCs) have not previously been considered, putative effects of thrombin on VGSC function were investigated in human isolated cardiomyocytes. METHODS AND
RESULTS: Sodium current (I(Na)) was recorded by the whole-cell patch-clamp method. Thrombin increased peak I(Na) amplitude in an activity-dependent manner, from 1 to 100 U/mL, with an apparent EC50 of 91+/-16 U/mL. When tested at 32 U/mL, thrombin-increased I(Na) was abolished by tetrodotoxin (50 micromol/L). Thrombin effects on I(Na) were reversible and repeatable, and 100 U/mL doubled peak I(Na) amplitude. Thrombin (32 U/mL) shifted I(Na) activation to hyperpolarized potentials without affecting steady-state inactivation, producing unusually large increases in window current. Hirudin (320 U/mL) or haloenol lactone suicide substrate (10 micromol/L) failed to significantly affect these effects of thrombin. In current-clamped cardiomyocytes, thrombin (32 U/mL) depolarized resting membrane potential by 10 mV.
CONCLUSIONS: Facilitation of VGSC activation causing large increases in window current is a major mechanism by which thrombin may promote ischemic sodium loading and injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379580     DOI: 10.1161/01.cir.0000034510.64828.96

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Blocking effect of methylflavonolamine on human Na(V)1.5 channels expressed in Xenopus laevis oocytes and on sodium currents in rabbit ventricular myocytes.

Authors:  Xin-rong Fan; Ji-hua Ma; Pei-hua Zhang; Jun-lian Xing
Journal:  Acta Pharmacol Sin       Date:  2010-02-22       Impact factor: 6.150

2.  Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.

Authors:  Elif Elmas; Thorsten Kaelsch; Christian Wolpert; Tim Sueselbeck; Thomas Bertsch; Carl Erik Dempfle; Martin Borggrefe
Journal:  Clin Cardiol       Date:  2006-04       Impact factor: 2.882

Review 3.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

4.  Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice.

Authors:  R Anzawa; M Bernard; S Tamareille; D Baetz; S Confort-Gouny; J P Gascard; P Cozzone; D Feuvray
Journal:  Diabetologia       Date:  2006-01-20       Impact factor: 10.122

5.  Thrombin receptor and ventricular arrhythmias after acute myocardial infarction.

Authors:  Lilong Tang; Chunyu Deng; Ming Long; Anli Tang; Shulin Wu; Yugang Dong; Louis D Saravolatz; Julius M Gardin
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

Review 6.  Hyperkalemic cardioplegia for adult and pediatric surgery: end of an era?

Authors:  Geoffrey P Dobson; Giuseppe Faggian; Francesco Onorati; Jakob Vinten-Johansen
Journal:  Front Physiol       Date:  2013-08-28       Impact factor: 4.566

7.  Protective effects of gallic acid on cardiac electrophysiology and arrhythmias during reperfusion in diabetes.

Authors:  Fatemeh Ramezani-Aliakbari; Mohammad Badavi; Mahin Dianat; Seyed Ali Mard; Akram Ahangarpour
Journal:  Iran J Basic Med Sci       Date:  2019-05       Impact factor: 2.699

8.  Decreased cardiac excitability secondary to reduction of sodium current may be a significant contributor to reduced contractility in a rat model of sepsis.

Authors:  Andrew Koesters; Kathrin L Engisch; Mark M Rich
Journal:  Crit Care       Date:  2014-03-26       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.